# Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07014449** · PHASE1 · RECRUITING · sponsor: **Hangzhou Weben Pharma Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia
- Relapsed Acute Myelogenous Leukemia
- Refractory Acute Myeloid Leukemia
- Hematologic Malignancy
- C-Myc
- Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** WBC100 QD

## Key facts

- **NCT ID:** NCT07014449
- **Lead sponsor:** Hangzhou Weben Pharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-03
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014449, "Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07014449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*